Alembic Pharmaceuticals Share Price Prediction 2027: Scenario Targets, Valuation and Technical Outlook
- October 9, 2026
- Posted by: Lakshit Sharma
- Category: Market
CMP Rs 789.95 (9 Oct 2026). 52W range Rs 635.80 to Rs 998.00. PE 22.82. 2027 base Rs 878, bull Rs 1,051.
Quick Answer
Alembic Pharmaceuticals share price prediction 2027 centres on a conservative case of Rs 843, a base case of Rs 878 and a bull case of Rs 1,051, against a current price of Rs 789.95. These targets scale today’s price by reported EPS growth at a constant PE multiple, so they rest on earnings the company has already delivered, not on broker forecasts. The base case implies 11.1% upside from today’s price. The daily technical setup reads bearish.
The Alembic Pharmaceuticals share price forecast comes down to earnings growth and the multiple investors pay for it, and the reported numbers give a measured answer. The stock trades at Rs 789.95 on NSE as of 9 October 2026, 20.8% below its 52-week high of Rs 998.00, after the company reported net profit of Rs 670.83 crore for FY26.
This Alembic Pharmaceuticals stock forecast 2027 builds conservative, base and bull scenarios from exchange-reported financials, shareholding data and daily price indicators, with every assumption shown.
Click Here – Get Free Investment Predictions
Alembic Pharmaceuticals Share Price Today and Key Data
The Alembic Pharmaceuticals share price today is Rs 789.95 on NSE, down 1.32% on the day. The market capitalisation stands at Rs 15,733 crore. Over the past year the price has fallen 15.1% from Rs 929.95. Every Alembic Pharmaceuticals stock forecast figure below starts from this price.
| Metric | Value |
|---|---|
| Company | Alembic Pharmaceuticals (APLLTD) |
| Current Price | Rs 789.95 |
| 52-Week High | Rs 998.00 (4 November 2025) |
| 52-Week Low | Rs 635.80 (23 March 2026) |
| Market Cap | Rs 15,733 crore |
| PE Ratio | 22.82 |
| Industry PE | 37.59 |
| PB Ratio | 2.77 |
| EPS (TTM) | Rs 35.08 |
| Return on Equity | 11.89% |
| Debt to Equity | 0.25 |
| Dividend Yield | 1.50% |
| Book Value per Share | Rs 288.70 |
What Is the Alembic Pharmaceuticals Share Price Prediction for 2027?
The Alembic Pharmaceuticals share price prediction for 2027 is a conservative case of Rs 843, a base case of Rs 878 and a bull case of Rs 1,051. Against Rs 789.95, these imply 6.7% upside, 11.1% upside and 33.0% upside. They are model scenarios built from reported EPS growth, not broker targets.
| Scenario | EPS Growth Basis | EPS Estimate | PE Multiple | Implied Value | Upside vs Current Price |
|---|---|---|---|---|---|
| Conservative Case | Lower of FY26 growth (15.7%) and 4-year CAGR (6.7%) | Rs 37.43 (+6.7%) | Unchanged from today (price to EPS ratio kept constant) | Rs 843 | +6.7% |
| Base Case | Average of the two | Rs 39.00 (+11.2%) | Unchanged from today (price to EPS ratio kept constant) | Rs 878 | +11.1% |
| Bull Case | Higher of the two | Rs 40.58 (+15.7%) | Re-rated 15.0% toward industry PE of 37.59 (still at or below it) | Rs 1,051 | +33.0% |
Each target takes today’s price of Rs 789.95 and scales it by the EPS growth assumed for that case, which is the same as holding the PE multiple constant. The conservative case uses the lower of the FY26 EPS growth and the 4-year EPS CAGR, the base case uses their average and the bull case uses the higher figure. The bull case also re-rates the PE multiple toward the industry level, because the stock trades below it. Together they form the Alembic Pharmaceuticals target price range for the FY27 outlook over the next 12 months, and the range is not a point estimate.
Alembic Pharmaceuticals Share Price Forecast: What Has to Go Right by 2027
Each Alembic Pharmaceuticals target price below depends on a specific EPS outcome, and the text states that outcome next to the number.
Conservative Case for the Alembic Pharmaceuticals Share Price Target: Rs 843
Reaching Rs 843 needs EPS to rise 6.7% to Rs 37.43 while the stock keeps its current PE multiple. That follows the slower 4-year EPS CAGR of 6.7%.
Base Case for the Alembic Pharmaceuticals Share Price Target: Rs 878
Reaching Rs 878 needs EPS to rise 11.2% to Rs 39.00, the average of the FY26 growth rate and the 4-year CAGR. Net profit growth of 12.2% in Q1 FY27 is at or above that pace, which supports the target.
Bull Case for the Alembic Pharmaceuticals Share Price Target: Rs 1,051
Reaching Rs 1,051 needs EPS to rise 15.7% to Rs 40.58 and the PE multiple to re-rate 15.0% toward the industry PE. That is above the 52-week high of Rs 998.00, so it would need a fresh breakout. A daily close above the nearest resistance level of Rs 812.31 (200-day EMA) would be the first technical confirmation.
Alembic Pharmaceuticals Financial Performance: Revenue, Profit and Margins
Alembic Pharmaceuticals earned net profit of Rs 670.83 crore on revenue of Rs 7,399.31 crore in FY26, with profit up 15.3% and revenue up 10.2% compared with FY25. Diluted EPS was Rs 34.33 against Rs 29.68 a year earlier, and that earnings base anchors the Alembic Pharmaceuticals share price forecast.
| Year | Revenue (Rs Cr) | Net Profit (Rs Cr) | EPS (Rs) | Operating Margin | Net Margin |
|---|---|---|---|---|---|
| FY22 | 5,356.25 | 520.94 | 26.50 | 17.53% | 9.73% |
| FY23 | 5,655.36 | 341.99 | 17.40 | 12.03% | 6.05% |
| FY24 | 6,256.93 | 615.82 | 31.33 | 15.42% | 9.84% |
| FY25 | 6,714.63 | 582.01 | 29.68 | 15.95% | 8.67% |
| FY26 | 7,399.31 | 670.83 | 34.33 | 15.06% | 9.07% |
In the latest reported quarter, Q1 FY27 (quarter ended June 2026), revenue was Rs 2,164.70 crore against Rs 1,717.22 crore a year earlier (+26.1%), and the bottom line was a net profit of Rs 172.36 crore against a net profit of Rs 153.63 crore (+12.2%). Operating margin was 16.15% versus 16.80% in the year-ago quarter. Cash flow from operations was Rs 782.73 crore in FY26 against Rs 87.96 crore in FY25. Together these figures set the earnings base for the Alembic Pharmaceuticals share price prediction.
Check the Univest Screener for live Alembic Pharmaceuticals fundamentals
Is Alembic Pharmaceuticals Overvalued or Undervalued Right Now?
Alembic Pharmaceuticals trades at a PE of 22.82 against an industry PE of 37.59, which places the stock at a 39.3% discount to the industry average. The price-to-book ratio is 2.77 on a book value of Rs 288.70 per share. Return on equity of 11.89% means the company earns Rs 11.89 of profit for every Rs 100 of shareholder equity.
Debt to equity is 0.25, so borrowings equal about 25% of shareholder equity. The company declared a dividend of Rs 12.00 per share for FY26, a yield of 1.50% at the current price. This valuation context frames the Alembic Pharmaceuticals stock price prediction for 2027 without relying on any outside forecast.
Alembic Pharmaceuticals Stock Analysis: Technical Outlook
Alembic Pharmaceuticals stock trades below its 50-day SMA of Rs 824.80 and below its 200-day EMA of Rs 812.31, and the combined daily indicators read bearish. The 52-week high of Rs 998.00 was set on 4 November 2025, while the 52-week low of Rs 635.80 came on 23 March 2026.
| Indicator | Reading | Signal |
|---|---|---|
| RSI (14) | 32.69 | Weak momentum |
| MACD (12,26,9) | -2.84 vs signal 2.87 | Bearish |
| ADX (14) | 29.09 | Established trend |
| Supertrend (10,3) | Price above Rs 776.58 | Bullish |
| 50-day SMA | Rs 824.80 | Price below |
| 200-day EMA | Rs 812.31 | Price below |
The nearest support level sits at Rs 776.58 (Supertrend) and Rs 635.80 (52-week low). The nearest resistance level sits at Rs 812.31 (200-day EMA) and Rs 824.80 (50-day SMA). A sustained move above the nearest resistance would support the Alembic Pharmaceuticals share price prediction 2027 base case, and this Alembic Pharmaceuticals stock analysis uses daily candles only. Chart signals add context to the Alembic Pharmaceuticals share price target without changing the earnings maths.
Alembic Pharmaceuticals Shareholding Pattern
Promoters hold 69.87% of Alembic Pharmaceuticals as of Jun 2026, up from 69.67% in Jun 2025 across the last 5 quarters. FII holding is 4.18% (up from 3.96% in Jun 2025) and DII holding is 15.94% (down from 16.46% in Jun 2025), which puts combined institutional holding at 20.12%. Public shareholders own 10.01%. Shareholding data is one input for any Alembic Pharmaceuticals stock forecast. Ownership is a useful cross-check on any Alembic Pharmaceuticals share price prediction.
Key Risks to the Alembic Pharmaceuticals Share Price Target for 2027
Earnings and Margin Risk
Operating margin has ranged from 12.03% to 17.53% between FY22 and FY26, so a slip toward the lower end would trim the EPS estimate behind the Alembic Pharmaceuticals stock forecast. Revenue was up 10.2% in FY26, and slower revenue growth would weigh on the profit path.
Size and Liquidity Risk
Market capitalisation stands at Rs 15,733 crore. Investors should check daily traded volumes and order book depth on NSE before sizing a position, because price moves can be sharper when volumes thin out. Liquidity is a practical constraint on any Alembic Pharmaceuticals stock price target.
Balance Sheet Risk
Debt to equity of 0.25 means borrowings stand at about 25% of shareholder equity. A rise in borrowing costs or a jump in debt would weigh on profit and on the multiple behind the Alembic Pharmaceuticals share price forecast.
Technical Risk
The daily indicators read bearish, so the targets above may need a technical turn before the price follows earnings. A daily close below Rs 776.58 (Supertrend) would weaken the setup further.
Conclusion
This Alembic Pharmaceuticals stock analysis puts the share price target range for 2027 at Rs 843 to Rs 1,051, with a base case of Rs 878 against Rs 789.95 today. The inputs are a PE of 22.82 that sits at a 39.3% discount to the industry average, EPS growth of 15.7% in FY26 and a daily technical setup that reads bearish. The next quarterly result will show which scenario is gaining ground. This analysis is educational, so consult a SEBI-registered advisor before acting on it.
Download the Univest iOS App or Univest Android App to track Alembic Pharmaceuticals live price and get daily stock recommendations.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Alembic Pharmaceuticals Share Price Prediction 2027
What is the Alembic Pharmaceuticals share price target for 2027?
Ans. The Alembic Pharmaceuticals share price forecast for 2027 has a conservative case of Rs 843, a base case of Rs 878 and a bull case of Rs 1,051. These are model scenarios based on reported EPS growth, and they are not guaranteed outcomes.
What is the Alembic Pharmaceuticals share price today?
Ans. Alembic Pharmaceuticals trades at Rs 789.95 on NSE as of 9 October 2026, down 1.32% on the day. The 52-week range is Rs 635.80 to Rs 998.00.
Is Alembic Pharmaceuticals a good stock to buy for 2027?
Ans. The data points in different directions: the PE of 22.82 is at a 39.3% discount to the industry average, EPS grew 15.7% in FY26 and the daily technical setup reads bearish. This article does not constitute investment advice, so consult a SEBI-registered advisor before deciding.
Can Alembic Pharmaceuticals stock reach Rs 1,051 in 2027?
Ans. Reaching Rs 1,051 needs EPS to rise 15.7% from Rs 35.08 and the PE multiple to re-rate toward the industry PE of 37.59, plus a daily close above Rs 812.31 (200-day EMA). This is a scenario, not a guarantee.
What are the support and resistance levels for Alembic Pharmaceuticals?
Ans. The nearest support levels are Rs 776.58 (Supertrend) and Rs 635.80 (52-week low), and the nearest resistance levels are Rs 812.31 (200-day EMA) and Rs 824.80 (50-day SMA).
What are the main risks for Alembic Pharmaceuticals stock in 2027?
Ans. The main risks to the Alembic Pharmaceuticals share price forecast are a fall in operating margin from the 12.03% to 17.53% range seen since FY22, slower revenue growth after FY26 revenue was up 10.2%, and thin trading volumes. Debt to equity of 0.25 adds balance sheet sensitivity.
How is the Alembic Pharmaceuticals target price for 2027 calculated?
Ans. Each target scales the current price by assumed EPS growth at a constant PE multiple. The conservative case uses 6.7% growth, the base case 11.2% and the bull case 15.7%, all drawn from the company’s reported FY26 and 4-year EPS growth.